Background
==========

Dodeca-2*E*,4*E*,8*E*,10*E/Z*-tetraenoic acid isobutylamides are the main alkamides in *Echinacea*preparations, which have been demonstrated to possess biological activities in various bio-assays, such as immune-modulating activities and effects on cannabinoid receptors \[[@B1]\]. Therefore, the evaluation of systemic availability of these active plant constituents is a major prerequisite for the interpretation of *in vitro*pharmacological testing. This study assessed the absolute and relative bioavailabilities of dodeca-2*E*,4*E*,8*E*,10*E/Z*-tetraenoic acid isobutylamides (tetraenes) administered as pure compounds or as an *Echinacea purpurea*root extract preparation.

Methods
=======

Ten rats received 0.75 mg/kg dodeca-2*E*,4*E*,8*E*,10*E/Z*-tetraenoic acid isobutylamides orally, pure and within 158.6 mg/kg *Echinacea purpurea*extract, or intravenously to compare the absorption and pharmacokinetic properties. Pharmacokinetic parameters and bioavailability data of tetraenes were obtained by non-compartmental analysis (NCA) using WinNonlin^®^5.2 software.

Results
=======

Mean dodeca-2*E*,4*E*,8*E*,10*E/Z*-tetraenoic acid isobutylamide plasma area under the concentration-time curve (AUC~0-∞~per dose) was 3.2 ± 0.3 min·ng/mL/μg and 1.0 ± 0.2 min·ng/mL/μg after i.v. and oral administration, respectively, and 1.5 ± 0.2 min·ng/mL/μg after oral administration of the *Echinacea*root extract. The absolute bioavailability of dodeca-2*E*,4*E*,8*E*,10*E/Z*-tetraenoic acid isobutylamides was 29%, which was increased to 47% (1.6 fold) by the administration of an *Echinacea*extract. The relative bioavailability was over 100%.

Conclusion
==========

Administration of a whole *Echinacea*extract increases blood exposure with no impact on C~max~. The high area under the curve concentration resulted in a longer elimination half-life with 123 min in comparison to 36 min after administration of the pure dodeca-2*E*,4*E*,8*E*,10*E/Z*-tetraenoic acid isobutylamides. The approximately 2-fold higher percentage of relative bioavailability achieved with the *Echinacea*root extract resulted in a 3.4 and 3.6 times higher terminal elimination half-life and mean residence time (MRT), respectively. A rapid absorption followed by a slower elimination phase was observed.
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